Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain zaps to fight weed addiction in schizophrenia?

NCT ID NCT04871048

Disease control Sponsor: Centre Hospitalier Universitaire de Saint Etienne Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a non-invasive brain stimulation technique called tDCS can reduce cannabis use in people with schizophrenia. 110 motivated participants will receive either real or sham stimulation over 5 days. Researchers will track changes in cannabis consumption, cravings, and overall functioning over 6 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
transcranial direct current stimulation (tDCS) – a non-invasive brain stimulation device
What this could lead to
If it works, this could offer a new, drug-free way to help people with schizophrenia cut down or stop cannabis use, improving their overall health.
What could go wrong
This is an early exploratory study with only 110 people. The effects may be small or temporary, and not everyone may benefit. Brain stimulation can cause mild discomfort or headache.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 110 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2023

Expected to finish

Jun 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Schizophrenia diagnostic according to DSM (Diagnostic and Statistical Manual of mental disorder) 5 criteria, without change in psychotropic treatment since at least 4 weeks * Moderate to severe cannabis use disorder according to DSM 5 criteria and active consumption during the last 7 days * Subjects motivated to reduce or quit their cannabis consumption * Patients with ambulatory compulsory care may be included Exclusion Criteria: * Other substance use disorder, excluding nicotine, according to DSM 5 criteria * Other current psychiatric disorder according to DSM 5 criteria, excluding personality disorder * Inpatient hospitalization * History of head injury, neurological disorder with cerebral consequence or severe unstable somatic disorder * Pregnancy or no contraception * Contraindications for tDCS and/or MRI (implanted material, uncontrolled epilepsy, intracranial hypertension)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cannabis use disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cannabis dependence schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cannabis-induced disorder Schizophrenia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    8 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CH Le Vinatier Service universitaire d'addictologie de Lyon

    NOT_YET_RECRUITING

    Bron, 69678, France

  • CH Saint-Cyr-au-Mont-d'Or service de psychiatrie

    NOT_YET_RECRUITING

    Saint-Cyr-au-Mont-d'Or, 69450, France

  • CHU Pôle de Psychiatrie Neurologie et Rééducation

    NOT_YET_RECRUITING

    La Tronche, 38700, France

  • CHU de Clermont-Ferrand Service de Psychiatrie

    NOT_YET_RECRUITING

    Clermont-Ferrand, 63000, France

  • CHU de Saint-Etienne

    RECRUITING

    Saint-Priest-en-Jarez, France

  • Centre Hospitalier Alpes Isère

    NOT_YET_RECRUITING

    Saint-Égrève, 38120, France

  • Centre Hospitalier Universitaire Service d'Addictologie et Pathologies Duelles

    NOT_YET_RECRUITING

    Clermont-Ferrand, 63000, France

  • Service Hospitalo-Universitaire d'Addictologie CHU de Dijon

    NOT_YET_RECRUITING

    Dijon, 21079, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.